Probiotics use was significantly associated with a better OS in NSCLC patients receiving anti‐PD‐L1 or anti‐PD‐1 therapy (HR = 0.50, 95% CI: 0.30–0.85, p = 0.01). Here, PDCD1 is linked to non-small cell lung carcinoma.